Aslan

Aslan sells Japanese rights to would-be Dupixent rival for $12M
Fierce Biotech
Thu, 06/22/23 - 10:41 pm
Aslan
Dupixent
Japan
eczema
Sanofi
Regeneron
eblasakimab
Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech
Endpoints
Mon, 11/11/19 - 11:00 am
Aslan
biliary tract cancer
clinical trials
gastic cancer
varlitinib
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Upcoming events – Atara and Aslan await validating results
EP Vantage
Fri, 08/2/19 - 10:40 am
Atara
Tab-cel
ATA188
multiple sclerosis
Aslan
varlitinib
Bristol-Myers reels back in an early-stage cancer drug prospect in $60M Asia deal
Endpoints
Wed, 08/10/16 - 09:56 am
Bristol-Myers Squibb
BMS-777607
Aslan
Asia
China Biotech Week In Review: Roche's China Strategy
Seeking Alpha
Sun, 11/6/11 - 12:43 pm
Roche
China National Biotechnology Group
Aslan
Alios BioPharma
ImmunoBiology Ltd
Healthgen Biotechnology
Array BioPharma Licenses Cancer Drug ARRY-543 to ASLAN Pharmaceuticals
Marketwatch
Wed, 07/13/11 - 11:55 am
Array Biopharma
ARRY-543
Aslan
HER2 Inhibitor
cancer